Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Post by garygpon May 21, 2021 1:21pm
303 Views
Post# 33248578

Who is steering the ship right now?

Who is steering the ship right now?It appears the helm hasn't been taken by the Boston Group just yet! 

Who in their right mind, would have allowed a release of this magnitude on a Friday,  leading into a long weekend when we and the market are starving for good news?  This seems like a rookie mistake to me.  Both Gene and Elliot should have their collective a$$es kicked around the block until they bleed.

This undynamic duo should be stripped of their authority and sent packing post haste.  Our only saving grace is Neil Cashman.  Send Gene and Elliot back to the flop house where they were found so they can join their drunken-drugged out compatriots.  They will be the most popular screwballs at the joint with their stolen shareholder funded bootie of millions.

What a pair of clowns.  We will succeed in spite of the foolishness and stupidity of this pair.

G.
<< Previous
Bullboard Posts
Next >>